![]() | |
Clinical data | |
---|---|
Other names | MLE-4901; AZD-4901; AZD-2624; AZ-12472520 |
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C26H25N3O3S |
Molar mass | 459.56 g·mol−1 |
3D model ( JSmol) | |
| |
|
Pavinetant ( INN , USAN ; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS). [1] [2] [3] It was also under investigation for the treatment of schizophrenia, [2] but development was discontinued for this indication due to lack of effectiveness. [1] [4] In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits. [1] [3]